Radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve, Belgium, has entered into an agreement with Bayer Schering Pharma Germany (Bayer) of Berlin for chemical process development and clinical trial dose supply of the PET tracer florbetaben for detecting Alzheimer's disease pathology.
Under the terms of the agreement, IBA will manufacture and supply Bayer and its trial partners with doses of florbetaben for clinical trials and receive several million euros in milestone payments and fees depending on the amount of florbetaben used in the clinical trials.
IBA also will develop a large-scale manufacturing process on its multipurpose automated synthesizer Synthera, and upgrade its PET manufacturing network for the availability of the compound for the clinical trials.
Florbetaben is a PET tracer in-licensed by Bayer that is undergoing clinical development for potential use in diagnostic imaging of beta amyloid deposits in the brain.
Related Reading
IBA to build proton center in Poland, August 2, 2010
IBA wins Swedish contract, July 8, 2010
IBA inks deal with Procure, July 6, 2010
IBA, Wilex tout Redectane results, May 18, 2010
IBA's sales decline in Q1, May 12, 2010
Copyright © 2010 AuntMinnie.com
